401 related articles for article (PubMed ID: 31571052)
1. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.
Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H
Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052
[TBL] [Abstract][Full Text] [Related]
2. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A
Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946
[TBL] [Abstract][Full Text] [Related]
4. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
5. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
6. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
Larsen SG; Goscinski MA; Dueland S; Steigen SE; Hofsli E; Torgunrud A; Lund-Iversen M; Dagenborg VJ; Flatmark K; Sorbye H
Br J Cancer; 2022 Mar; 126(5):726-735. PubMed ID: 34887523
[TBL] [Abstract][Full Text] [Related]
7. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O
Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
9. Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases.
Morgan RB; Dhiman A; Sood D; Ong CT; Wu X; Shergill A; Polite B; Turaga KK; Eng OS
J Surg Oncol; 2023 Apr; 127(5):831-840. PubMed ID: 36636792
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
[TBL] [Abstract][Full Text] [Related]
11. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases.
Flood MP; Jain A; Mitchell C; Hewitt C; Ramsay R; Michael M; Heriot AG; Tie J
Eur J Surg Oncol; 2022 Oct; 48(10):2218-2225. PubMed ID: 35750576
[TBL] [Abstract][Full Text] [Related]
12. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
[TBL] [Abstract][Full Text] [Related]
14. RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer.
Morgan Z; Chow BE; Strong EA; Tsai S; Christians K; Mogal H; Gamblin TC; Clarke CN
J Surg Res; 2019 Aug; 240():130-135. PubMed ID: 30928770
[TBL] [Abstract][Full Text] [Related]
15. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial.
Glockzin G; Rochon J; Arnold D; Lang SA; Klebl F; Zeman F; Koller M; Schlitt HJ; Piso P
BMC Cancer; 2013 Feb; 13():67. PubMed ID: 23391248
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
17. Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC.
Zhang C; Plambeck BD; Craig ME; Tu A; Mikus RJ; Shostrom V; McDermott SP; Igbinigie I; Brown K; Cushman-Vokoun A; Foster JM
J Surg Oncol; 2021 Jun; 123(7):1599-1609. PubMed ID: 33667317
[TBL] [Abstract][Full Text] [Related]
18. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
19. Impact of Primary Tumor Location and Genomic Alterations on Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Colorectal Peritoneal Metastases.
Hamed AB; Shuai Y; Derby J; Holtzman MP; Ongchin M; Bartlett DL; Pingpank JF; Pai R; Singhi A; Choudry HA
Ann Surg Oncol; 2023 Jul; 30(7):4459-4470. PubMed ID: 37085655
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
